Vol 32, No 1 (2025)
Original Article
Published online: 2025-02-06

open access

Page views 357
Article views/downloads 172
Get Citation

Connect on Social Media

Connect on Social Media

Shaping cardiac diagnostics: The role of myocardial tissue mapping in unraveling ring-like fibrosis

Katarzyna E. Gil1, Vien T. Truong2, Saurabh Rajpal1, Karolina M. Zareba13
Pubmed: 39912881
Cardiol J 2025;32(1):62-72.

Abstract

Background: Patients with non-ischemic cardiomyopathy exhibit a range of myocardial fibrosis (MF) patterns on cardiovascular magnetic resonance (CMR) late gadolinium enhancement (LGE) imaging. Data suggests that ring-like MF is associated with worse prognosis. In the present study it was sought to analyze the prevalence of parametric mapping abnormalities in ring-like MF and their prognostic value for arrhythmic events. 

Methods: Patients undergoing clinical CMR at 1.5T/3T were evaluated for ring-like MF defined as midwall/subepicardial fibrosis involving ≥ 3 contiguous left ventricular segments. CMR protocol included cine imaging, T1 and T2 mapping, and LGE. Mean native T1, ECV, and T2 values and a number of mid short axis segments with elevated values were calculated.  LGE extent was assessed segmentally. Arrhythmic outcomes were defined as appropriate device shock, premature ventricular contractions ≥ 10%, non-sustained/sustained ventricular tachycardia, or ventricular fibrillation. 

Results: In total 49 patients (53 ± 17 years, 26.5% female) were analyzed. Many patients had elevated global/segmental mapping values: 45%/76% in native T1, 57%/57% in T2, and 57%/78% in ECV. During median follow-up of 12 months, arrhythmic events occurred in 65% of patients.  There was no association between native T1/T2 elevation or number of LGE segments and arrhythmic outcomes. There was a significant association between ECV and arrhythmic outcomes, both septal ECV (p = 0.036) and any segmental ECV elevation (p = 0.03). 

Conclusion: T1 and T2 myocardial tissue abnormalities are common in patients with ring-like MF. ECV elevation was associated with arrhythmic events in this cohort. Further studies are needed to establish the diagnostic and prognostic value of parametric mapping in patients with ring-like MF.

Article available in PDF format

View PDF Download PDF file

References

  1. Muser D, Nucifora G, Muser D, et al. Prognostic Value of Nonischemic Ringlike Left Ventricular Scar in Patients With Apparently Idiopathic Nonsustained Ventricular Arrhythmias. Circulation. 2021; 143(14): 1359–1373.
  2. Augusto JB, Eiros R, Nakou E, et al. Dilated cardiomyopathy and arrhythmogenic left ventricular cardiomyopathy: a comprehensive genotype-imaging phenotype study. Eur Heart J Cardiovasc Imaging. 2020; 21(3): 326–336.
  3. Ortiz-Genga MF, Cuenca S, Dal Ferro M, et al. Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol. 2016; 68(22): 2440–2451.
  4. Corrado D, Marra MP, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. International Journal of Cardiology. 2020; 319: 106–114.
  5. Bietenbeck M, Meier C, Korthals D, et al. Possible Causes and Clinical Relevance of a "Ring-Like" Late Gadolinium Enhancement Pattern. JACC Cardiovasc Imaging. 2024; 17(1): 104–106.
  6. Tschöpe C, Ammirati E, Bozkurt B, et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021; 18(3): 169–193.
  7. Protonotarios A, Arbelo E, Gimeno JR, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023; 44(37): 3503–3626.
  8. Corrado D, Zorzi A, Cipriani A, et al. Evolving Diagnostic Criteria for Arrhythmogenic Cardiomyopathy. J Am Heart Assoc. 2021; 10(18): e021987.
  9. Smith ED, Lakdawala NK, Papoutsidakis N, et al. Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. Circulation. 2020; 141(23): 1872–1884.
  10. Bariani R, Rigato I, Cason M, et al. Genetic Background and Clinical Features in Arrhythmogenic Left Ventricular Cardiomyopathy: A Systematic Review. J Clin Med. 2022; 11(15).
  11. Schelbert EB, Fridman Y, Wong TC, et al. Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. J Am Heart Assoc. 2015; 4(12): e002613.
  12. Cheng RK, Masri SC. Extracellular Volume as an Imaging Biomarker for Incident Heart Failure. Circ Cardiovasc Imaging. 2019; 12(12): e010152.
  13. Laohabut I, Songsangjinda T, Kaolawanich Y, et al. Myocardial Extracellular Volume Fraction and T1 Mapping by Cardiac Magnetic Resonance Compared Between Patients With and Without Type 2 Diabetes, and the Effect of ECV and T2D on Cardiovascular Outcomes. Front Cardiovasc Med. 2021; 8: 771363.
  14. Youn JC, Hong YJ, Lee HJ, et al. Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study. Eur Radiol. 2017; 27(9): 3924–3933.
  15. Schelbert EB, Fridman Y, Wong TC, et al. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome. JAMA Cardiol. 2017; 2(9): 995–1006.
  16. Gil KE, Mikrut K, Mazur J, et al. Risk stratification in patients with structurally normal hearts: Does fibrosis type matter? PLoS One. 2023; 18(12): e0295519.
  17. O'Brien AT, Gil KE, Varghese J, et al. T2 mapping in myocardial disease: a comprehensive review. J Cardiovasc Magn Reson. 2022; 24(1): 33.
  18. Spieker M, Haberkorn S, Gastl M, et al. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J Cardiovasc Magn Reson. 2017; 19(1): 38.
  19. Baig M, Galazka P, Dakwar O, et al. PREVALENCE OF MYOCARDIAL EDEMA WITH T2 MAPPING IN HYPERTROPHIC CARDIOMYOPATHY. Journal of the American College of Cardiology. 2021; 77(18): 1303.
  20. Lehtonen J, Uusitalo V, Pöyhönen P, et al. Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis. Eur Heart J. 2023; 44(17): 1495–1510.
  21. Kramer CM, Barkhausen J, Bucciarelli-Ducci C, et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020; 22(1): 1–18.
  22. Cerqueira MD, Weissman NJ, Dilsizian V, et al. American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation. 2002; 105(4): 539–542.
  23. Haaf P, Garg P, Messroghli DR, et al. Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review. J Cardiovasc Magn Reson. 2016; 18(1): 1–12.
  24. Schelbert EB, Fridman Y, Wong TC, et al. Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage. J Am Heart Assoc. 2015; 4(12): e002613.
  25. Messroghli DR, Moon JC, Ferreira VM, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson. 2017; 19(1): 75.
  26. Flett A, Hasleton J, Quarta G, et al. The Full Width Half Maximum technique is superior for LGE quantification regardless of its aetiology. Journal of Cardiovascular Magnetic Resonance. 2010; 12(S1).
  27. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997–4126.
  28. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, et al. Reference ranges ("normal values") for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson. 2020; 22(1): 87.
  29. Spieker M, Katsianos E, Gastl M, et al. T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2018; 19(5): 574–582.
  30. Yang EY, Ghosn MG, Khan MA, et al. Myocardial Extracellular Volume Fraction Adds Prognostic Information Beyond Myocardial Replacement Fibrosis. Circ Cardiovasc Imaging. 2019; 12(12): e009535.
  31. Wong TC, Piehler KM, Kang IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014; 35(10): 657–664.
  32. Wong TC, Piehler KM, Kang IA, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012; 126(10): 1206–1216.
  33. Lopez-Ayala JM, Pastor-Quirante F, Gonzalez-Carrillo J, et al. Genetics of myocarditis in arrhythmogenic right ventricular dysplasia. Heart Rhythm. 2015; 12(4): 766–773.
  34. Bauce B, Basso C, Rampazzo A, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. 2005; 26(16): 1666–1675.
  35. Hall CL, Akhtar MM, Sabater-Molina M, et al. Filamin C variants are associated with a distinctive clinical and immunohistochemical arrhythmogenic cardiomyopathy phenotype. Int J Cardiol. 2020; 307: 101–108.
  36. Ghawanmeh M, Simon Frances B, Kerai A, et al. Management of Recurrent Myocarditis Due to Desmoplakin Cardiomyopathy: Diagnostic and Therapeutic Challenges. JACC Case Rep. 2022; 4(1): 59–62.
  37. Cipriani A, Bauce B, De Lazzari M, et al. Arrhythmogenic Right Ventricular Cardiomyopathy: Characterization of Left Ventricular Phenotype and Differential Diagnosis With Dilated Cardiomyopathy. J Am Heart Assoc. 2020; 9(5): e014628.
  38. Di Marco A, Brown PF, Bradley J, et al. Extracellular volume fraction improves risk-stratification for ventricular arrhythmias and sudden death in non-ischaemic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2023; 24(4): 512–521.
  39. Castrichini M, De Luca A, De Angelis G, et al. Magnetic Resonance Imaging Characterization and Clinical Outcomes of Dilated and Arrhythmogenic Left Ventricular Cardiomyopathies. J Am Coll Cardiol. 2024; 83(19): 1841–1851.
  40. Aquaro GD, De Gori C, Faggioni L, et al. Diagnostic and prognostic role of late gadolinium enhancement in cardiomyopathies. Eur Heart J Suppl. 2023; 25(Suppl C): C130–C136.
  41. de Frutos F, Ochoa JP, Fernández AI, et al. Late gadolinium enhancement distribution patterns in non-ischaemic dilated cardiomyopathy: genotype-phenotype correlation. Eur Heart J Cardiovasc Imaging. 2023; 25(1): 75–85.
  42. Kawel-Boehm N, Hetzel SJ, Ambale-Venkatesh B, et al. Reference ranges ("normal values") for cardiovascular magnetic resonance (CMR) in adults and children: 2020 update. J Cardiovasc Magn Reson. 2020; 22(1): 1–63.